FIH of RMC-6236, tri-complex RASmulti(ON) inhibitor #targets23 Alex Spira, M.D.

.Alex Spira, M.D. explains the importance of next-generation sequencing and the future of lung cancer care and targeted therapies at #ASCO21 . #LCSM

Exciting phase 2 adagrasib data from Alex Spira, M.D. & cross-trial comparison with sotorasib. Similar efficacy, perhaps higher AEs with adagrasib, encouraging 33% intracranial ORR among treated/stable CNS mets. Approval soon? Biomarkers of response remain immature. #ASCO22 #LCSM

Adgrasib registration phase 2 is out, which allows to draw sone in perfect comparisons with sotorasib Alex Spira, M.D. Suki Kaur Padda David S. Hong MD Ferdinandos Skoulidis #ASCO22

TPS8609: Phase 3 trial of durvalumab combined with domvanalimab (AB154, anti-TIGIT) following concurrent chemoradiotherapy in patients with unresectable stage III NSCLC (PACIFIC-8, NCT05211895) by Alex Spira, M.D.. #ASCO23 #LCSM

#ESMO23 Lung II Highlights w/ Alex Spira, M.D.

- #PAPILLON
- #MARIPOSA
- #MARIPOSA 2
- #LIBRETTO431

Full 📢:
- Oncbrothers.com/lung2-esmo23
- targetedonc.com/data-dialogue-…
- Also on the “Oncology Brothers” podcast

GI to follow!

#MedTwitter #OncTwitter ESMO - Eur. Oncology #lcsm #LungCancer

Needle core biopsy is a simple and quick way to get a sample of tissue for lab analysis.Stunning example of how this diagnosis can be made with the naked eye #sunscreen Melanoma Research Foundation American Cancer Society NIH Virginia Cancer Specialists Alex Spira, M.D. SIR RFS JVIR Vascular Inst of VA

KRYSTAL-1/Adagrasib NSCLC 2nd line KRAS G12C+ ORR 43% PFS 6.5m OS 12.6m IC-ORR 33%
Promising activity but more TRAE than Sotorasib? Great presentation and thought provoking discussion Alex Spira, M.D. Sukhmani (Suki) Padda MD #ASCO22 #LCSM

Great article thanks to our Caris Life Sciences POA group and Julia Judd chadi nabhan MD, MBA, FACP gilberto lopes Hossein Borghaei, DO Hirva Mamdani Chul Kim Rafeh Naqash, MD #LCSM @kRasKickers Alex Spira, M.D. Ed Kim Stephen V Liu, MD Memorial Cancer Institute Memorial Healthcare System FLASCO OLACANCER

First up at the ADC Oral abstract session at #WCLC20 #LCSM , Alex Spira, M.D. presented updated data on Dato-DXd, a TROP2 ADC.

Nice to see this in print. Cohort of patients with KRAS G12C NSCLC with untreated brain metastases prospectively enrolled and treated with adagrasib. Clear CNS activity. ascopubs.org/doi/full/10.12… Joshua Sabari, MD Journal of Clinical Oncology Shirish Gadgeel Jared Weiss Alex Spira, M.D.

💥 #ASCO22 #LCSM
Concomitant publication NEJM for the KRAYSTAL-1 ph2 trial, just presented by Alex Spira, M.D.
Another step forward for the KRAS-g12C mutant NSCLC…& much more is coming! nejm.org/doi/full/10.10…

My wonderful colleague and friend Christian Rolfo giving an elegant talk on #liquidbiopy in #PhaseI #clinicaltrials at #ETOncology23 organized by Binaytara Foundation. Vivek Subbiah, MD Dr. Nagla Abdel Karim Binay Shah, MD, MHA Alex Spira, M.D. Icahn School of Medicine at Mount Sinai International Society of Liquid Biopsy Rafeh Naqash, MD Stephen V Liu, MD

KRYSTAL-1: #adagrasib in KRAS G12C mutant NSCLC presented by Dr. Alex Spira, M.D.

N=116
ORR=43% (DOR: 8.5 months)
Median PFS=6.5 months (95% CI: 4.7-8.4)
Median OS=12.6 months (95% CI: 9.2-19.2)

A great targeted therapy option for KRAS G12C mutant NSCLC

#ASCO22 #LCSM

🚨KRYSTAL-1: Adagrasib in prev treated KRASG12C-mut #NSCLC
➡️ ORR 43%, DCR 89%
➡️ DOR 8.5 mo
➡️ PFS 6.5 mo
➡️ OS 12.6 mo
➡️ NO diff in subgroup analysis
➡️ IC-ORR 33%
➡️ Grade 3-4 AEs 43%
OncoAlert KRASKickers Alex Spira, M.D. Shirish Gadgeel #LCSM

#ASCO22 🎥 starts today! Looking forward to a presentations in #LCSM 📄📰 starting at 1 pm CST today!
Amazing line up Erica Nakajima Alex Spira, M.D. Charu Aggarwal, MD, MPH, FASCO Karen Reckamp, MD, MS Enriqueta Felip Joel W. Neal, MD, PhD and others!!
Before we start 🎥 ⬇️ for an overview of #LCSM landscape!

Cheers - to friends at the holidays Benjamin Levy Alex Spira, M.D.

#Targets23 Dr. Alex Spira, M.D. presents early look at RMC-6236, a first-in-class RAS(ON) inhibitor in #KRAS tumors. Safety data very reassuring and example of response in KRAS G12D pancreatic cancer and KRAS G12D NSCLC! Huge unmet need, very exciting - await data at #ESMO23 !

What’s the #Future of #drugdevelopment ? Alex Spira, M.D. & I tried to tackle the important question with three great speakers- Drs. Alice Chen National Cancer Institute, Mohamad Salkini Virginia Cancer Specialists, Asrar AlAhmadi, MD, MAS-CR Ohio State. #SCLC #ADCs Vivek Subbiah, MD Binay Shah, MD, MHA Dr. Nagla Abdel Karim #ETOncology23